search.noResults

search.searching

dataCollection.invalidEmail
note.createNoteMessage

search.noResults

search.searching

orderForm.title

orderForm.productCode
orderForm.description
orderForm.quantity
orderForm.itemPrice
orderForm.price
orderForm.totalPrice
orderForm.deliveryDetails.billingAddress
orderForm.deliveryDetails.deliveryAddress
orderForm.noItems
BIOTECHNOLOGY


A biobank proved a valuable resource for an international research project looking into colorectal cancer


cancer every year. It is well known that the development from benign precursors- polyps or adenomas to colorectal cancer takes about 10 years. During this time period, these precursors can be diagnosed and removed during colonoscopy, thus preventing the development of colorectal cancer.


BENEFITS OF BIOBANKS C


olorectal cancer is one of the most common cancers worldwide. In Austria, approximately 5,000 people are diagnosed with colorectal


on Translational Cancer Research (TRANSCAN), and by the Austrian Science Fund FWF. Te consortium involves the Medical University of Vienna, the German Cancer Research Center (DKFZ) in Heidelberg, the Universities of Maastricht and Wageningen in the Netherlands, the International Agency for Research on Cancer (IARC) in Lyon, France, and BEVITAL in Norway.


BIOBANKS: VALUABLE RESOURCES FOR RESEARCH Over the past 16 years, a research team from the Medical University of Vienna headed by Andrea Gsur has established a comprehensive biobank that includes DNA, plasma samples and clinical data of more than 16,000 individuals with colorectal cancer, adenomas and a control group. Te CORSA (Colorectal Cancer Study of Austria) biobank was established in close cooperation with the screening programme “Burgenland Prevention Trial of Colorectal Cancer Disease with Immunological Testing” (B-PREDICT) in the Austrian province of Burgenland. CORSA is as a valuable resource for the international research project MetaboCCC. MetaboCCC is supported by the European network ERA-NET


44 www.scientistlive.com


IDENTIFICATION OF METABOLITE SIGNATURES In the course of MetaboCCC more than 2,000 plasma samples from individuals with colorectal cancer, adenomas and controls, which are confirmed by colonoscopy to be free of adenomas and colon cancer were examined. All participating TRANSCAN countries (Austria, Germany, Netherlands and


Norway) sent their plasma samples to the expert laboratory at the IARC in France for metabolomic measurements. Measurements have been conducted by mass spectroscopy. Metabolomics is an innovative and


powerful approach by which a large number of metabolites are systematically screened. Metabolomics has been proven as a high-throughput method for the discovery of new biomarkers. “Metabolomics has the advantage of an easy transition from a profiling technology to a clinical assay,” explains Andrea Gsur. Te MetaboCCC consortium allowed the measurement in a large sample size and enabled the validation of results in independent study population (discovery and validation set).


ABOVE: Colon cancer is one of the most common cancers worldwide TOP: The comprehensive biobank includes DNA, plasma samples and clinical data


15 SIGNIFICANT METABOLITES IDENTIFIED Te aim of this project was to identify metabolite signatures that are associated with all stages in the development of colorectal cancer. In a recent publication resulting from the project, metabolomic profiles of patients from the Germany cohort were used as a discovery set and samples from Austria were used for validation. Tereby, 15 statistically significant metabolites could be identified. Within the MetaboCCC consortium, statistical analyses of the comprehensive data set is ongoing and further publications are in preparation. Te newly discovered metabolites could contribute to the development of tailored therapeutic approaches and prevention strategies.


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72